MetLife Investment Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

MetLife Investment Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-38,562	Closed	-$677K	–	2608
2021 Q3	$677K	Hold	38,562	–	–	0.01%	1354
2021 Q2	$374K	Buy	+38,562	New	+$363K	﹤0.01%	1747

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

MetLife Investment Management's TRIL Position: Q4 2021 in Review

MetLife Investment Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 38,562 shares — an estimated $677K sold.

MetLife Investment Management first reported a position in TRIL in Q2 2021 and held it in 2 quarters. The position peaked at $677K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

MetLife Investment Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
MetLife Investment Management sold 38,562 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $677K.
MetLife Investment Management first reported a position in Trillium Therapeutics Inc. in Q2 2021 and held it in 2 quarters.
MetLife Investment Management's Trillium Therapeutics Inc. position peaked at $677K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on MetLife Investment Management's 13F filing for Q4 2021, filed 15 Feb 2022.